SCHEMBL3569207

SCHEMBL3569207

O=C(c1ccc(-c2nc3ccccc3[nH]2)cc1)c1ccc2c(c1)OCO2

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.75
▸ MAPT P10636 5/20 0.75
▸ KMT2A Q03164 5/20 0.75
▸ MEN1 O00255 4/20 0.75
▸ RAB9A P51151 3/20 0.75
▸ CYP3A4 P08684 2/20 0.75
▸ CYP2D6 P10635 2/20 0.75
▸ CYP2C19 P33261 2/20 0.75
▸ POLB P06746 1/20 0.75
▸ CYP2C9 P11712 1/20 0.75
▸ CHEK2 O96017 6/20 0.74
▸ NPC1 O15118 3/20 0.66
▸ CYP1A2 P05177 1/20 0.66
▸ ALDH1A1 P00352 6/20 0.59
▸ HPGD P15428 3/20 0.59
▸ HTT P42858 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ MAPK1 P28482 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4410984 0.86 KDM4E (1.00) KDM4EMAPTKMT2AMEN1RAB9A
SCHEMBL1378452 0.85 CHEK2 (0.84) KDM4EMAPTKMT2AMEN1RAB9A
SCHEMBL3341124 0.84 PARP1 (0.67) KDM4EMAPTKMT2AMEN1RAB9A
SCHEMBL5178035 0.81 CHEK2 (0.67) KDM4EMAPTKMT2AMEN1RAB9A
SCHEMBL16782299 0.80 MAPT (1.00) KDM4EMAPTKMT2AMEN1RAB9A
SCHEMBL3565185 0.80 CHEK2 (0.69) KDM4EMAPTKMT2AMEN1RAB9A
SCHEMBL3567003 0.79 CHEK2 (0.84) CHEK2
SCHEMBL3922737 0.79 CHEK2 (0.67) KDM4EMAPTKMT2AMEN1RAB9A
SCHEMBL5897634 0.77 CHEK2 (0.68) KDM4EMAPTKMT2ARAB9APOLB
SCHEMBL4165387 0.76 SIRT2 (0.71) KDM4EMAPTKMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687639-B2 Substituted benzimidazoles and imidazo-[4,5]-pyridines JANSSEN PHARMACEUTICA N.V. (BE) 2010-03-30 — — US disclosed
US-20060252793-A1 Substituted benzimidazoles and imidazo-[4,5]-pyridines BW CONVERTING AB (SE) 2006-11-09 — — US disclosed
US-7132440-B2 Substituted benzimidazoles and imidazo-[4,5]-pyridines JANSSEN PHARMACEUTICA, N.V. (BE) 2006-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252793-A1 Substituted benzimidazoles and imidazo-[4,5]-pyridines CDKN1A, DDB1, TMBIM6 KDM4E 3815/4885MAPT 4562/4885KMT2A 4404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback